UPCC 09517: Phase II study of Pembrolizumab and Itacitinib (INCB039110) for First Line Treatment of Metastatic Non-Small Cell Lung Cancer Expressing PD-L1
Brief description of study
The main purpose of this study is to examine the efficacy of adding itacitinib (also known as INCB039110) to pembrolizumab in patients with previously untreated metastatic non-small cell lung cancer.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
lung cancer
-
Age: - 99 Years
-
Gender: All
Updated on
29 Jan 2020.
Study ID: 828910